Ryujiro Suzuki

1.3k total citations
48 papers, 697 citations indexed

About

Ryujiro Suzuki is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Ryujiro Suzuki has authored 48 papers receiving a total of 697 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pulmonary and Respiratory Medicine, 20 papers in Oncology and 11 papers in Molecular Biology. Recurrent topics in Ryujiro Suzuki's work include Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Research Studies (9 papers) and Asthma and respiratory diseases (7 papers). Ryujiro Suzuki is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Research Studies (9 papers) and Asthma and respiratory diseases (7 papers). Ryujiro Suzuki collaborates with scholars based in Japan, Switzerland and Australia. Ryujiro Suzuki's co-authors include Kenzo Takagi, Hiroyuki Taniguchi, Kenichi Yamaki, Tatsuo Satake, Fumio Taki, Hiroaki Kume, Keizo Torii, Masashi Kondo, Osamu Nishiyama and Yasuhiro Kondoh and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and CHEST Journal.

In The Last Decade

Ryujiro Suzuki

47 papers receiving 679 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ryujiro Suzuki Japan 15 341 205 152 146 73 48 697
Shizuo Hasegawa Japan 17 345 1.0× 291 1.4× 70 0.5× 224 1.5× 78 1.1× 41 790
Hiroyuki Ohbayashi Japan 13 297 0.9× 249 1.2× 68 0.4× 125 0.9× 82 1.1× 55 671
Susan Kennedy United States 9 151 0.4× 133 0.6× 55 0.4× 247 1.7× 46 0.6× 10 659
Toshihiko Kaise Japan 16 200 0.6× 254 1.2× 54 0.4× 131 0.9× 143 2.0× 47 777
Daniela N. Petrusca United States 18 303 0.9× 175 0.9× 89 0.6× 525 3.6× 139 1.9× 39 963
Nveed Chaudhary Germany 9 551 1.6× 196 1.0× 48 0.3× 244 1.7× 74 1.0× 10 892
Garry J. Douglas United States 14 111 0.3× 128 0.6× 133 0.9× 146 1.0× 174 2.4× 34 548
Christopher Lambers Austria 15 431 1.3× 145 0.7× 85 0.6× 210 1.4× 77 1.1× 35 763
Elizabeth Joseloff United States 14 689 2.0× 93 0.5× 84 0.6× 294 2.0× 59 0.8× 21 1.0k
Tamyra Downs United States 14 95 0.3× 57 0.3× 128 0.8× 179 1.2× 75 1.0× 19 830

Countries citing papers authored by Ryujiro Suzuki

Since Specialization
Citations

This map shows the geographic impact of Ryujiro Suzuki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryujiro Suzuki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryujiro Suzuki more than expected).

Fields of papers citing papers by Ryujiro Suzuki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryujiro Suzuki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryujiro Suzuki. The network helps show where Ryujiro Suzuki may publish in the future.

Co-authorship network of co-authors of Ryujiro Suzuki

This figure shows the co-authorship network connecting the top 25 collaborators of Ryujiro Suzuki. A scholar is included among the top collaborators of Ryujiro Suzuki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryujiro Suzuki. Ryujiro Suzuki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kimura, Tomoki, Hiroyuki Taniguchi, Naohiro Watanabe, et al.. (2016). Phase II Study of Carboplatin and Pemetrexed in Advanced EGFR-wild-type Non-squamous Non-small Cell Lung Cancer: The Central Japan Lung Study Group Trial 0906.. PubMed. 36(4). 1767–71. 4 indexed citations
2.
Katô, Toshio, Masahiro Morise, Masahiko Ando, et al.. (2016). Can we predict the development of serious adverse events (SAEs) and early treatment termination in elderly non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy?. Journal of Cancer Research and Clinical Oncology. 142(7). 1629–1640. 3 indexed citations
3.
Takahashi, Kosuke, Hiroshi Saito, Yoshinori Hasegawa, et al.. (2014). First-line gefitinib therapy for elderly patients with non-small cell lung cancer harboring EGFR mutation: Central Japan Lung Study Group 0901. Cancer Chemotherapy and Pharmacology. 74(4). 721–727. 27 indexed citations
4.
Morise, Masahiro, Hiroyuki Taniguchi, Hideo Saka, et al.. (2014). Phase II study of erlotinib for previously treated patients with EGFR wild-type non-small-cell lung cancer, following EGFR mutation status reevaluation with the Scorpion Amplified Refractory Mutation System. Molecular and Clinical Oncology. 2(6). 991–996. 7 indexed citations
5.
Sato, Kazuhide, Yoshihiro Takeyama, Akira Ando, et al.. (2014). Granulocyte Colony-Stimulating Factor-Producing Carcinoma of Unknown Primary Site. Case Reports in Oncology. 7(3). 780–788. 29 indexed citations
6.
Sato, Kazuhide, Yoshihiro Takeyama, Toshio Kato, et al.. (2012). CBDCA + Pemetrexed + Bevacizumab and Its Maintenance Chemotherapy in a Case of Solitary Breast Metastasis from a Lung Adenocarcinoma Resistant to Gefitinib. Case Reports in Oncology. 5(3). 546–553. 11 indexed citations
7.
Kitagawa, Chiyoe, et al.. (2012). Phase I and pharmacologic study of weekly amrubicin in patients with refractory or relapsed lung cancer: Central Japan Lung Study Group (CJLSG) 0601 trial. Cancer Chemotherapy and Pharmacology. 69(5). 1379–1385. 8 indexed citations
8.
Ichikawa, Motoshi, Ryujiro Suzuki, Kensuke Kataoka, et al.. (2010). Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin: A multi-center phase II study. Lung Cancer. 69(3). 319–322. 6 indexed citations
9.
Usami, Noriyasu, Kohei Yokoi, Yoshinori Hasegawa, et al.. (2010). Phase II study of carboplatin and gemcitabine as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial. International Journal of Clinical Oncology. 15(6). 583–587. 13 indexed citations
10.
Kondoh, Yasuhiro, Hiroyuki Taniguchi, Kensuke Kataoka, et al.. (2010). Prognostic factors in rapidly progressive interstitial pneumonia. Respirology. 15(2). 257–264. 14 indexed citations
11.
Suzuki, Ryujiro, Masashi Yamamoto, Hideo Saka, et al.. (2008). A phase II study of carboplatin and paclitacel with meloxicam. Lung Cancer. 63(1). 72–76. 17 indexed citations
12.
Kataoka, Kensuke, Ryujiro Suzuki, Hiroyuki Taniguchi, et al.. (2006). Phase I/II Trial of Docetaxel and Carboplatin as a First-Line Therapy in Patients with Stage IV Non-Small-Cell Lung Cancer. Lung. 184(3). 133–139. 5 indexed citations
13.
Shimizu, Makoto, Masashi Kondo, Yasushi Ito, et al.. (2004). Soluble Fas and Fas ligand provide new information on metastasis and response to chemotherapy in SCLC patients. Cancer Detection and Prevention. 29(2). 175–180. 19 indexed citations
14.
Nishiyama, Osamu, Keisuke Kato, Hiroaki Kume, et al.. (2003). Asthma Health Status: Influence of Disease Severity Categorized by Peak Expiratory Flow. Journal of Asthma. 40(3). 281–287. 11 indexed citations
15.
Suzuki, Ryujiro, et al.. (2001). Matrix Metalloproteinases and Tissue lnhibitors of Matrix Metalloproteinases in Sputum from Patients with Bronchial Asthma. Journal of Asthma. 38(6). 477–484. 32 indexed citations
16.
Ohbayashi, Hiroyuki, Kenichi Yamaki, Ryujiro Suzuki, & K. Takagi. (1998). Effects of uroguanylin and guanylin against antigen-induced bronchoconstriction and airway microvascular leakage in sensitized guinea-pigs. Life Sciences. 62(20). 1833–1844. 13 indexed citations
17.
Katoh, Toshiyuki, et al.. (1998). Computed tomographic findings in non‐specific interstitial pneumonia/fibrosis. Respirology. 3(2). 69–75. 10 indexed citations
18.
Kume, Hiroaki, et al.. (1995). A Case of Metastatis to the Iris from Lung Cancer Presenting with Decrease of Visual Activity and an Ocular Mass.. Haigan. 35(7). 931–935. 1 indexed citations
19.
Matsumoto, Kohei, et al.. (1993). [A case of drug induced pneumonitis caused by oral etoposide].. PubMed. 31(7). 903–7. 2 indexed citations
20.
Taki, Fumio, et al.. (1991). Erythromycin Reduces the Severity of Bronchial Hyperresponsiveness in Asthma*. CHEST Journal. 99(3). 670–673. 120 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shizuo Hasegawa Breakdown of academic impact, for papers by Hiroyuki Ohbayashi Breakdown of academic impact, for papers by Susan Kennedy Breakdown of academic impact, for papers by Toshihiko Kaise Breakdown of academic impact, for papers by Daniela N. Petrusca Breakdown of academic impact, for papers by Nveed Chaudhary Breakdown of academic impact, for papers by Garry J. Douglas Breakdown of academic impact, for papers by Christopher Lambers Breakdown of academic impact, for papers by Elizabeth Joseloff Breakdown of academic impact, for papers by Tamyra Downs
Rankless by CCL
2026